low - Diabetes care products are non-discretionary medical consumables with utilization driven by disease prevalence rather than economic conditions. However, consumer out-of-pocket costs can affect compliance rates during economic stress, and healthcare utilization patterns (doctor visits, prescription fills) show modest correlation with employment and insurance coverage stability. The business is more sensitive to healthcare policy and pharmaceutical innovation cycles than GDP growth.

Rising interest rates increase debt service costs on the company's ~$1.3B term loan and revolving credit facilities, directly pressuring free cash flow available for debt reduction or potential shareholder returns. The spin-off capital structure was established in a low-rate environment, making the company vulnerable to refinancing risk. Higher rates also compress valuation multiples for low-growth healthcare businesses, as investors rotate toward higher-yielding alternatives. Limited impact on operational demand, as diabetes patients continue purchasing consumables regardless of rate environment.

value - The stock trades at distressed multiples (0.6x P/S, 5.2x EV/EBITDA) reflecting structural concerns about diabetes care market evolution. The 30% free cash flow yield attracts deep value investors betting on stabilization and debt paydown, while the negative equity and declining revenue deter growth-oriented funds. Special situations investors may view this as a potential restructuring or strategic alternative candidate given the challenged standalone profile. High short interest likely reflects skepticism about the company's ability to offset GLP-1 headwinds.